Dimethyl fumarate in relapsing-remitting multiple sclerosis: Rationale, mechanisms of action, pharmacokinetics, efficacy and safety

Divyanshu Dubey, Bernd C. Kieseier, Hans P. Hartung, Bernhard Hemmer, Clemens Warnke, Til Menge, William A. Miller-Little, Olaf Stuve

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Dimethyl fumarate (DMF), a fumaric acid ester, is a new orally available disease-modifying agent that was recently approved by the US FDA and the EMA for the management of relapsing forms of multiple sclerosis (MS). Fumaric acid has been used for the management of psoriasis, for more than 50 years. Because of the known anti-inflammatory properties of fumaric acid ester, DMF was brought into clinical development in MS. More recently, neuroprotective and myelin-protective mechanism actions have been proposed, making it a possible candidate for MS treatment. Two Phase III clinical trials (DEFINE, CONFIRM) have evaluated the safety and efficacy of DMF in patients with relapsing-remitting MS. Being an orally available agent with a favorable safety profile, it has become one of the most commonly prescribed disease-modifying agents in the USA and Europe.

Original languageEnglish (US)
Pages (from-to)339-346
Number of pages8
JournalExpert review of neurotherapeutics
Volume15
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Relapsing-Remitting Multiple Sclerosis
Multiple Sclerosis
Fumarates
Pharmacokinetics
Safety
Phase III Clinical Trials
Myelin Sheath
Psoriasis
Anti-Inflammatory Agents
Dimethyl Fumarate
Therapeutics

Keywords

  • dimethyl fumarate
  • experimental autoimmune encephalomyelitis
  • immunology
  • multiple sclerosis
  • pharmacology

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Dimethyl fumarate in relapsing-remitting multiple sclerosis : Rationale, mechanisms of action, pharmacokinetics, efficacy and safety. / Dubey, Divyanshu; Kieseier, Bernd C.; Hartung, Hans P.; Hemmer, Bernhard; Warnke, Clemens; Menge, Til; Miller-Little, William A.; Stuve, Olaf.

In: Expert review of neurotherapeutics, Vol. 15, No. 4, 01.04.2015, p. 339-346.

Research output: Contribution to journalReview article

Dubey, Divyanshu ; Kieseier, Bernd C. ; Hartung, Hans P. ; Hemmer, Bernhard ; Warnke, Clemens ; Menge, Til ; Miller-Little, William A. ; Stuve, Olaf. / Dimethyl fumarate in relapsing-remitting multiple sclerosis : Rationale, mechanisms of action, pharmacokinetics, efficacy and safety. In: Expert review of neurotherapeutics. 2015 ; Vol. 15, No. 4. pp. 339-346.
@article{3882423e4bee420caa064ec525c0d1a5,
title = "Dimethyl fumarate in relapsing-remitting multiple sclerosis: Rationale, mechanisms of action, pharmacokinetics, efficacy and safety",
abstract = "Dimethyl fumarate (DMF), a fumaric acid ester, is a new orally available disease-modifying agent that was recently approved by the US FDA and the EMA for the management of relapsing forms of multiple sclerosis (MS). Fumaric acid has been used for the management of psoriasis, for more than 50 years. Because of the known anti-inflammatory properties of fumaric acid ester, DMF was brought into clinical development in MS. More recently, neuroprotective and myelin-protective mechanism actions have been proposed, making it a possible candidate for MS treatment. Two Phase III clinical trials (DEFINE, CONFIRM) have evaluated the safety and efficacy of DMF in patients with relapsing-remitting MS. Being an orally available agent with a favorable safety profile, it has become one of the most commonly prescribed disease-modifying agents in the USA and Europe.",
keywords = "dimethyl fumarate, experimental autoimmune encephalomyelitis, immunology, multiple sclerosis, pharmacology",
author = "Divyanshu Dubey and Kieseier, {Bernd C.} and Hartung, {Hans P.} and Bernhard Hemmer and Clemens Warnke and Til Menge and Miller-Little, {William A.} and Olaf Stuve",
year = "2015",
month = "4",
day = "1",
doi = "10.1586/14737175.2015.1025755",
language = "English (US)",
volume = "15",
pages = "339--346",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "4",

}

TY - JOUR

T1 - Dimethyl fumarate in relapsing-remitting multiple sclerosis

T2 - Rationale, mechanisms of action, pharmacokinetics, efficacy and safety

AU - Dubey, Divyanshu

AU - Kieseier, Bernd C.

AU - Hartung, Hans P.

AU - Hemmer, Bernhard

AU - Warnke, Clemens

AU - Menge, Til

AU - Miller-Little, William A.

AU - Stuve, Olaf

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Dimethyl fumarate (DMF), a fumaric acid ester, is a new orally available disease-modifying agent that was recently approved by the US FDA and the EMA for the management of relapsing forms of multiple sclerosis (MS). Fumaric acid has been used for the management of psoriasis, for more than 50 years. Because of the known anti-inflammatory properties of fumaric acid ester, DMF was brought into clinical development in MS. More recently, neuroprotective and myelin-protective mechanism actions have been proposed, making it a possible candidate for MS treatment. Two Phase III clinical trials (DEFINE, CONFIRM) have evaluated the safety and efficacy of DMF in patients with relapsing-remitting MS. Being an orally available agent with a favorable safety profile, it has become one of the most commonly prescribed disease-modifying agents in the USA and Europe.

AB - Dimethyl fumarate (DMF), a fumaric acid ester, is a new orally available disease-modifying agent that was recently approved by the US FDA and the EMA for the management of relapsing forms of multiple sclerosis (MS). Fumaric acid has been used for the management of psoriasis, for more than 50 years. Because of the known anti-inflammatory properties of fumaric acid ester, DMF was brought into clinical development in MS. More recently, neuroprotective and myelin-protective mechanism actions have been proposed, making it a possible candidate for MS treatment. Two Phase III clinical trials (DEFINE, CONFIRM) have evaluated the safety and efficacy of DMF in patients with relapsing-remitting MS. Being an orally available agent with a favorable safety profile, it has become one of the most commonly prescribed disease-modifying agents in the USA and Europe.

KW - dimethyl fumarate

KW - experimental autoimmune encephalomyelitis

KW - immunology

KW - multiple sclerosis

KW - pharmacology

UR - http://www.scopus.com/inward/record.url?scp=84925846204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925846204&partnerID=8YFLogxK

U2 - 10.1586/14737175.2015.1025755

DO - 10.1586/14737175.2015.1025755

M3 - Review article

C2 - 25800129

AN - SCOPUS:84925846204

VL - 15

SP - 339

EP - 346

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 4

ER -